CXCL13/CXCR5 Signalling is Pivotal to Preserve Motor Neurons in Amyotrophic Lateral Sclerosis

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2020 Nov 8

PMID 33161233

Citations 14

Authors

Maria Chiara Trolese

Alessandro Mariani

Mineko Terao

Massimiliano De Paola

Paola Fabbrizio

Francesca Sironi

Mami Kurosaki

Silvia Bonanno

Stefania Marcuzzo

Pia Bernasconi

Francesca Trojsi

Eleonora Aronica

Caterina Bendotti

Giovanni Nardo

Affiliations

Soon will be listed here.

Abstract

Background: CXCL13 is a B and T lymphocyte chemokine that mediates neuroinflammation through its receptor CXCR5. This chemokine is highly expressed by motoneurons (MNs) in Amyotrophic Lateral Sclerosis (ALS) SOD1G93A (mSOD1) mice during the disease, particularly in fast-progressing mice. Accordingly, in this study, we investigated the role of this chemokine in ALS.

Methods: We used in vitro and in vivo experimental paradigms derived from ALS mice and patients to investigate the expression level and distribution of CXCL13/CXCR5 axis and its role in MN death and disease progression. Moreover, we compared the levels of CXCL13 in the CSF and serum of ALS patients and controls.

Findings: CXCL13 and CXCR5 are overexpressed in the spinal MNs and peripheral axons in mSOD1 mice. CXCL13 inhibition in the CNS of ALS mice resulted in the exacerbation of motor impairment (n = 4/group;Mean_Diff.=27.81) and decrease survival (n = 14_Treated:19.2 ± 1.05wks, n = 17_Controls:20.2 ± 0.6wks; 95% CI: 0.4687-1.929). This was corroborated by evidence from primary spinal cultures where the inhibition or activation of CXCL13 exacerbated or prevented the MN loss. Besides, we found that CXCL13/CXCR5 axis is overexpressed in the spinal cord MNs of ALS patients, and CXCL13 levels in the CSF discriminate ALS (n = 30) from Multiple Sclerosis (n = 16) patients with a sensitivity of 97.56%.

Interpretation: We hypothesise that MNs activate CXCL13 signalling to attenuate CNS inflammation and prevent the neuromuscular denervation. The low levels of CXCL13 in the CSF of ALS patients might reflect the MN dysfunction, suggesting this chemokine as a potential clinical adjunct to discriminate ALS from other neurological diseases.

Funding: Vaccinex, Inc.; Regione Lombardia (TRANS-ALS).

Citing Articles

Dynamic human gut microbiome and immune shifts during an immersive psychosocial intervention program.

Zhou X, Ganz A, Rayner A, Cheng T, Oba H, Rolnik B Brain Behav Immun. 2024; 125:428-443.

PMID: 39701328 PMC: 11903166. DOI: 10.1016/j.bbi.2024.12.027.

Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases.

Zheng K, Chen M, Xu X, Li P, Yin C, Wang J Cell Mol Biol Lett. 2024; 29(1):134.

PMID: 39472796 PMC: 11523778. DOI: 10.1186/s11658-024-00653-y.

Dynamic Human Gut Microbiome and Immune Shifts During an Immersive Psychosocial Therapeutic Program.

Zhou X, Ganz A, Rayner A, Cheng T, Oba H, Rolnik B bioRxiv. 2024; .

PMID: 38979211 PMC: 11230355. DOI: 10.1101/2024.06.26.600881.

Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations.

Rogers M, Schultz D, Karnaros V, Shepheard S Brain Commun. 2023; 5(6):fcad287.

PMID: 37946793 PMC: 10631861. DOI: 10.1093/braincomms/fcad287.

The pathogenic mechanism of TAR DNA-binding protein 43 (TDP-43) in amyotrophic lateral sclerosis.

Wang X, Hu Y, Xu R Neural Regen Res. 2023; 19(4):800-806.

PMID: 37843214 PMC: 10664110. DOI: 10.4103/1673-5374.382233.

References

Banerjee R, Mosley R, Reynolds A, Dhar A, Jackson-Lewis V, Gordon P . Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One. 2008; 3(7):e2740. PMC: 2481277. DOI: 10.1371/journal.pone.0002740. View

Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J . CXCL13/CXCR5 signaling axis in cancer. Life Sci. 2019; 227:175-186. DOI: 10.1016/j.lfs.2019.04.053. View

Huang H, Liu Y, Wang L, Li W . Age-related macular degeneration phenotypes are associated with increased tumor necrosis-alpha and subretinal immune cells in aged Cxcr5 knockout mice. PLoS One. 2017; 12(3):e0173716. PMC: 5345864. DOI: 10.1371/journal.pone.0173716. View

Lazarini F, Tham T, Casanova P, Arenzana-Seisdedos F, Dubois-Dalcq M . Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia. 2003; 42(2):139-48. DOI: 10.1002/glia.10139. View

Nardo G, Trolese M, Verderio M, Mariani A, De Paola M, Riva N . Counteracting roles of MHCI and CD8 T cells in the peripheral and central nervous system of ALS SOD1 mice. Mol Neurodegener. 2018; 13(1):42. PMC: 6085701. DOI: 10.1186/s13024-018-0271-7. View

Smith J, Braziel R, Paoletti S, Lipp M, Uguccioni M, Rosenbaum J . Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2002; 101(3):815-21. DOI: 10.1182/blood-2002-05-1576. View

Naor S, Keren Z, Bronshtein T, Goren E, Machluf M, Melamed D . Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol. 2009; 256(8):1228-35. DOI: 10.1007/s00415-009-5097-3. View

Kim Y, Jang S, Shin Y, Jo Y, Yoon B, Nam S . Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy. Sci Rep. 2019; 9(1):16535. PMC: 6848485. DOI: 10.1038/s41598-019-52643-2. View

Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J . Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010; 11(1-2):38-45. DOI: 10.3109/17482960903545334. View

10.

De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M . Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012; 18:971-81. PMC: 3459480. DOI: 10.2119/molmed.2012.00020. View

11.

Nardo G, Trolese M, De Vito G, Cecchi R, Riva N, Dina G . Immune response in peripheral axons delays disease progression in SOD1 mice. J Neuroinflammation. 2016; 13(1):261. PMC: 5055725. DOI: 10.1186/s12974-016-0732-2. View

12.

Boulanger L . Immune proteins in brain development and synaptic plasticity. Neuron. 2009; 64(1):93-109. DOI: 10.1016/j.neuron.2009.09.001. View

13.

Nardo G, Trolese M, Tortarolo M, Vallarola A, Freschi M, Pasetto L . New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. Brain Pathol. 2016; 26(2):237-47. PMC: 8029191. DOI: 10.1111/bpa.12351. View

14.

Boulanger L, Shatz C . Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci. 2004; 5(7):521-31. DOI: 10.1038/nrn1428. View

15.

Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos A . Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation?. Acta Neurol Scand. 2010; 122(6):425-9. DOI: 10.1111/j.1600-0404.2010.01333.x. View

16.

Brettschneider J, Del Tredici K, Toledo J, Robinson J, Irwin D, Grossman M . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013; 74(1):20-38. PMC: 3785076. DOI: 10.1002/ana.23937. View

17.

Hardiman O, Al-Chalabi A, Chio A, Corr E, Logroscino G, Robberecht W . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017; 3:17071. DOI: 10.1038/nrdp.2017.71. View

18.

Rupprecht T, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C . The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2010; 6:42. PMC: 2811704. DOI: 10.1186/1742-2094-6-42. View

19.

Nissen M, Nilsson A, Forsberg J, Milthers J, Wirenfeldt M, Bonde C . Use of Cerebrospinal Fluid Biomarkers in Diagnosis and Monitoring of Rheumatoid Meningitis. Front Neurol. 2019; 10:666. PMC: 6606769. DOI: 10.3389/fneur.2019.00666. View

20.

Kwon M, Shin H, Cui Y, Kim H, Thi A, Choi J . CCL2 Mediates Neuron-Macrophage Interactions to Drive Proregenerative Macrophage Activation Following Preconditioning Injury. J Neurosci. 2015; 35(48):15934-47. PMC: 6605453. DOI: 10.1523/JNEUROSCI.1924-15.2015. View